Approved Study Database
| Ref. No. | Scientific Title | Principal investigator |
|---|---|---|
| 2001.489 | A Randomized, Double-Blind, Placebo-Controlled, Parallel Study of The Therapeutic Effect And Safety Of A Traditional Chinese Medicine (TCM) For Atopic Dermatitis In Children | Prof. HON Ellis Kam Lun |
| 2002.013 | A Randomized, Double-Blind, Placebo-Controlled, Parallel Pros. Study to Evaluate the Effect of a Herbal Preparation With Compound Formula of Danshen and Radix Puerariae as Cardiovascular Tonic in Cardiac Patient | Prof. Woo Kam Sang |
| 2002.179 | A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Trial Assessing The Rate of Decline of Lung Function with Tiotropium 18mcg Inhalation Capsule Once Daily in Patients with Chronic Obstructive Pulmonary Disease(COPD) | Prof. Hui Shu Cheong David |
| 2007.025 | A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Trial Assessing the Rate of Decline of Lung Function with Tiotropium 18 mcg Inhalation Capsule Once Daily in Patients with Chronic Obstructive Pulmonary Disease (COPD) | Dr. Chan Hok Sum |
| 2017.612 | A randomized, double-blind, placebo-controlled, parallel group study to evaluate the efficacy and safety of CNP520 in participants at risk for the onset of clinical symptoms of Alzheimer’s Disease (AD) |
Prof. MOK Chung Tong 莫仲棠 |
| 2005.253 | A Randomized, Double-blind, Placebo-Controlled, Multicentre Phase 3 Study to Evaluate the Long-term Safety of Alvimopan 0.5mg Twice Daily for 12 Months for the Treatment of Opioid-induced Bowel Dysfunction in Adults Taking Opioid Therapy for Persistent Non-Cancer Pain | Prof. Gin Tony |
| 2005.272 | A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase IIb Study to Evaluate the Efficacy and Safety of Multiple Alvimopan Dosage Regimens for the Treatment of Opioid-Induced Bowel Dysfunction in Cancer Pain Subjects (SB-767905/008) | Prof. Gin Tony |
| 2011.181 | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER, PARALLEL-GROUP STUDY TO EVALUATE THE EFFICACY AND SAFETY OF BRIVARACETAM IN SUBJECTS (_16 TO 80 YEARS OLD) WITH PARTIAL ONSET SEIZURES | Professor Patrick Kwan |
| 2019.039 | A randomized, double-blind, placebo-controlled, multicenter, parallel-group study to evaluate the efficacy and safety of adjunctive Brivaracetam in Asian Subjects (≥16 to 80 years of age) with partial seizures with or without secondary generalization |
Dr. LEUNG Ho Wan 梁浩雲醫生 |
| 2025.027 | A randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy, safety, and tolerability of pelacarsen (TQJ230) with background inclisiran in participants with atherosclerotic cardiovascular disease, and elevated LDL-C and Lp(a) |
Prof. TAN Guangming 譚廣明 |
| 2012.489 | A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess Cardiovascular Outcomes Following Treatment with MK-3102 in Subjects with Type 2 Diabetes Mellitus | Dr. LUK Andrea On Yan |
| 2012.488 | A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess Cardiovascular Outcomes Following Treatment with MK-3102 in Subjects with Type 2 Diabetes Mellitus | Dr. TSANG Chiu Chi |
| 2012.480 | A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess Cardiovascular Outcomes Following Treatment with MK-3102 in Subjects with Type 2 Diabetes Mellitus | Dr. OZAKI Risa |
| 2012.479 | A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess Cardiovascular Outcomes Following Treatment with MK-3102 in Subjects with Type 2 Diabetes Mellitus | Prof. LEE Alex Pui Wai |
| 2012.474 | A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess Cardiovascular Outcomes Following Treatment with MK-3102 in Subjects with Type 2 Diabetes Mellitus | Prof. WONG Samuel |
| 2004.099 | A Randomized, Double-Blind, Placebo-Controlled, Multicenter Evaluation of the Efficacy and Safety of Tegaserod (6mg b.I.d.), Administered Orally for 12 Weeks, in Male Patients with Chronic Constipation | Dr. Wu Che Yuen Justin |
| 2014.055 | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTI-CENTER TRIAL TO EVALUATE THE SAFETY AND EFFICACY OF ECULIZUMAB IN PATIENTS WITH RELAPSING NEUROMYELITIS OPTICA (NMO) | Dr. LAU Alexander Yuk Lun |
| 2013.293 | A randomized, double-blind, placebo-controlled, multi-center study to assess the safety and efficacy of different oral doses of BAY 94-8862 in subjects with type 2 diabetes mellitus and the clinical diagnosis of diabetic nephropathy | Dr. OZAKI Risa |
| 2012.333 | A Randomized, Double-blind, Placebo-controlled, Comparative Phase 3 Multicenter Study to Evaluate the Safety and Efficacy of BA058 for Injection for Prevention of Fracture in Ambulatory Postmenopausal Women with Severe Osteoporosis and at Risk of Fracture | Dr Liu Po Lung Paul |
| 2011.029 | A Randomized, Double-Blind, Placebo-controlled, 3-Arm, Parallel-Group, 26-Week, Multicenter Study With a 26-Week Extension, to Evaluate the Efficacy, Safety and Tolerability of Canagliflozin in the Treatment of Subjects With Type 2 Diabetes Mellitus Who Have Moderate Renal Impairment | Dr. Ozaki Risa |
| 2011.621 | A Randomized, Double-Blind, Placebo-Controlled Trial to Investigate Safety and Efficacy of Cerebrolysin in Patients with Traumatic Brain Injury | Prof. POON Wai Sang |
| 2011.284 | A randomized, double-blind, placebo-controlled trial of the efficacy and safety of DEB025/Alisporivir in combination with peg-IFN | Prof. Chan Lik Yuen Henry |
| 2011.180 | A randomized, double-blind, placebo-controlled trial of the efficacy and safety of DEB025/Alisporivir in combination with peg-IFN | Dr Hui Aric Josun |
| 2022.411 | A Randomized, Double-blind, Placebo-controlled Study to Investigate the Efficacy and Safety of Depemokimab in Adults with Hypereosinophilic Syndrome (HES) |
Dr. WONG Raymond Siu Ming 王紹明 |
| 2009.494 | A Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of CNTO 328 (Anti-IL-6 Monoclonal Antibody) Plus Best Supportive Care Compared With Best Supportive Care in Subjects With Multicentric Castleman Disease | Dr. WONG Raymond Siu Ming |
| 2005.462 | A Randomized, Double-blind, Placebo-controlled Study on Treatment of Nocturia with Desmopressin in Women | Prof. Chan Shing Chee Symphorosa |
| 2012.191 | A randomized, double-blind, placebo-controlled phase III study of regorafenib plus best supportive care (BSC) versus placebo plus BSC in Asian subjects with metastatic colorectal cancer (CRC) who have progressed after standard therapy (CONCUR) | Prof. Ma Brigette Buig - Yue |
| 2024.591 | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE II CLINICAL STUDY EVALUATING THE EFFICACY AND SAFETY OF DR10624 INJECTION IN SUBJECTS AT HIGH RISK OF LIVER FIBROSIS WITH METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE AND METABOLIC DYSFUNCTION AND ALCOHOL ASSOCIATED STEATOTIC LIVER DISEASE | Prof. WONG Vincent Wai Sun |
| 2010.599 | A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ORAL PF-04136309 500MG BID IN SUBJECTS WITH CHRONIC HCV INFECTION AND RAISED AMINOTRANSFERASES | Prof Chan Lik-yuen Henry |
| 2023.041 | A randomized, double-blind, placebo-controlled multicenter study to evaluate the effect of inclisiran on preventing major adverse cardiovascular events in high-risk primary prevention patients (VICTORION-1 PREVENT) |
Prof. YAN Bryan Ping Yen 甄秉言教授 |
| 2006.223 | A Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Safety and Efficacy of Cerebrolysin in Patients with Acute Ischemic Stroke | Prof. Poon Wai Sang |
| 2012.557 | A Randomized, Double-Blind, Placebo-Controlled 52-Week Study to Assess Adverse Events of Special Interest in Adults with Active, Autoantibody-Positive Systemic Lupus Erythematosus Receiving Belimumab | Prof. TAM Lai Shan |
| 2009.591 | A Randomized, Double-blind, Placebo- and Comparator-Controlled, Dose Response Study of CS-1036 in Patients with Type 2 Diabetes | Professor Tomlinson Brian |
| 2009.590 | A Randomized, Double-blind, Placebo- and Comparator-Controlled, Dose Response Study of CS-1036 in Patients with Type 2 Diabetes | Professor Chan Chung Ngor Juliana |
| 2009.589 | A Randomized, Double-blind, Placebo- and Comparator-Controlled, Dose Response Study of CS-1036 in Patients with Type 2 Diabetes | Dr Tsang Chiu Chi |
| 2009.120 | A Randomized, Double-Blind, Placebo- and Active-Controlled, Parallel-Group, Multicenter Study to Determine the Efficacy and Safety of Albiglutide When Used in Combination with Metformin Compared with Metformin Plus Sitagliptin, Metformin Plus Glimepiride, and Metformin Plus Placebo in Subjects with Type 2 Diabetes Mellitus | Dr. Tsang Chiu Chi |
| 2009.109 | A Randomized, Double-Blind, Placebo- and Active-Controlled, Parallel-Group, Multicenter Study to Determine the Efficacy and Safety of Albiglutide When Used in Combination with Metformin Compared with Metformin Plus Sitagliptin, Metformin Plus Glimepiride, and Metformin Plus Placebo in Subjects with Type 2 Diabetes Mellitus | Dr Ozaki Risa |
| 2009.112 | A Randomized, Double-Blind, Placebo- and Active-Controlled, Parallel-Group, Multicenter Study to Determine the Efficacy and Safety of Albiglutide Administered in Combination with Metformin and Glimepiride Compared with Metformin Plus Glimepiride and Placebo and with Metformin Plus Glimepiride and Pioglitazone in Subjects with Type 2 Diabetes Mellitus | Dr. Chow C.C. Francis |
| 2009.122 | A Randomized, Double-Blind, Placebo- and Active-Controlled, Parallel-Group, Multicenter Study to Determine the Efficacy and Safety of Albiglutide Administered in Combination With Metformin and Glimepiride Compared with Metformin Plus Glimepiride and Placebo and With Metformin Plus Glimepiride and Pioglitazone in Subjects With Type 2 Diabetes Mellitus | Dr. Tsang Chiu Chi |
| 2016.533 | A Randomized, Double-blind, Placebo- and Active-controlled, Multicenter, Phase 3 Study to Assess the Efficacy and Safety of Filgotinib Administered for 52 weeks in Combination with Methotrexate to Subjects with Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Methotrexate |
Prof. TAM Lai Shan 譚麗珊 |
| 2007.183 | A Randomized, Double-Blind, Placebo- and Active Comparator-Controlled Dose-Response Study of Rivoglitazone (CS-011) in Patients with Type 2 Diabetes | Prof. Kong P.S. Alice |
| 2002.451 | A Randomized, Double-blind, Placebo Controlled, Multicentre, Phase III Study of Tarceva | Prof. Mok Tony |
| 2009.464 | A Randomized, Double-Blind, Placebo Controlled Study to evaluate the health benefits of Cordyceps mycelium capsules based on the theory of Traditional Chinese Medicine | Prof. Ho Walter K.K. |
| 2007.292 | A Randomized, Double-Blind, Pilot Study Comparing the Saftey and Efficacy of Betamare Plus Chemotherapy to Chemotherapy Alone in the Prevention and Treatment of Cancer Anorexia and Cachexia in Patients with Advanced Non-Small Cell Lung Cancer | Dr. Lam Kwok Chi |
| 2012.559 | A randomized, double-blind, parallel, placebo-controlled study assessing the efficacy and safety of sarilumab added to non-biologic DMARD therapy in patients with rheumatoid arthritis who are inadequate responders to or intolerant of TNF-α antagonists | Prof. TAM Lai Shan |
| 2007.100 | A Randomized, Double-Blind, Parallel-Group, Study of Cardiovascular Safety in Osteoarthritis or Rheumatoid Arthritis Patients with or at High Risk for Cardiovascular Disease Comparing Celecoxib with Naproxen and Ibuprofen | Prof. LAM Yat Yin |
| 2013.514 | A Randomized, Double-Blind, Parallel-Group, Placebo- and Active- Controlled, Multi-center Study to Evaluate the Efficacy, Safety and Tolerability of Combinations of Solifenacin Succinate and Mirabegron Compared to Solifenacin Succinate and Mirabegron Monotherapy in the Treatment of Overactive Bladder | Dr. CHAN Symphorosa Shing Chee |
| 2013.536 | A Randomized, Double-Blind, Parallel-Group, Placebo- and Active- Controlled, Multi-center Study to Evaluate the Efficacy, Safety and Tolerability of Combinations of Solifenacin Succinate and Mirabegron Compared to Solifenacin Succinate and Mirabegron Monotherapy in the Treatment of Overactive Bladder | Prof. NG Chi Fai |
| 2005.287 | A Randomized, Double-Blind, Parallel-Group, Placebo Controlled Study of Esomeprazole I.v. (Bolus Infusion of 80mg Followed by a Continuous Infusion of 8mg per hour) Administered for 72 hours to Assess Prevention of Rebleeding in Subjects that Have Undergone Successful Primary Endoscopic Haemostasis of A Bleeding Peptic Ulcer ・the PUB Study | Prof. Sung Joseph |
| 2013.594 | A Randomized, Double-Blind, Parallel-Group, Active-Controlled, Multi-center Study to Evaluate the Long-Term Safety and Efficacy of Combination of Solifenacin Succinate with Mirabegron Compared to Solifenacin Succinate and Mirabegron Monotherapy in Subjects with Overactive Bladder | Dr. CHAN Symphorosa Shing Chee |
Page 226 of 265.